Home / Transcripts / Yatharth Hospital & Trauma Care Services Limited (YATHARTH) · November 14, 2025

Yatharth Hospital & Trauma Care Services Limited (YATHARTH) Earnings Call Transcript

November 14, 2025

National Stock Exchange of India IN Health Care Health Care Providers and Services earnings 61 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, everyone, and welcome to the Yatharth Hospital & Trauma Care Services Limited FY 2026 earnings call, hosted by Elara Capital. Please be reminded that every participant line is in listen-only mode, and there will be a chance to ask questions once the presentation wraps up. If you require assistance at any point during this conference call, please signal an operator by pressing star then zero on your touch-tone phone. Kindly note that this conference is being recorded. I'll now hand things over to Mr. Kashish Thakur from Elara Capital. Thank you, and over to you, sir.

Moderator operator
#2

Thank you, sir. Oh, and good afternoon to all of you. Speaking for Elara Capital, I'd like to extend a welcome to each of you on this FY 2026 earnings conference call for Yatharth Hospital & Trauma Care Services Limited. Joining us from management are Mr. Yatharth Tyagi, Whole-time Director; Mr. Amit Kumar Singh, Group CEO; Mr. Nitin Gupta, President, Finance and Chief Operating Officer; Mr. Pankaj Prabhakar, Group CFO; Mr. Ashutosh Kumar Jha, Group Finance Strategy, Mergers and Acquisition, IR; and Mr. Sonu Goyal, Group Finance Controller. At this point I'll pass the call to Mr. Tyagi so he can give his opening remarks, after which we'll open the floor for the question and answer session. Over to you, Mr. Tyagi. Thank you.

Yatharth Tyagi executive
#3

Good afternoon, everyone, and welcome to the earnings conference call for Yatharth Hospital & Trauma Care Services Limited, covering the quarter that closed on September 30, 2025. With me on the call today are Mr. Amit Kumar Singh, our Group CEO; Mr. Pankaj Prabhakar, Group CFO; Mr. Nitin Gupta, Group COO and President, Finance; Mr. Ashutosh Kumar Jha, Group Chief Strategy, M&A and Investor Relations; and Mr. Sonu Goyal, Group Finance Controller. You can find our earnings presentation on the stock exchange as well as on our website, and we hope you've had a chance to go through it. For Yatharth Hospital, this quarter represents a major phase of progress on both the operational and strategic fronts, delivering industry-leading performance, with revenue at its highest level ever and a better. One key positive milestone this quarter came from the income tax authorities: an order unfreezing the provisionally attached properties and fixed assets of the company, which restores full financial flexibility for our expansion initiatives. That milestone represents an important step toward resolving a long-pending income tax matter. In keeping with the highest standard of governance, we are pleased to announce that Mr. Ramesh Krishnan has been appointed as Independent Director. He is a healthcare veteran whose three decades of experience include leading hospitals and private equity in the healthcare space. At our latest annual general meeting, we also appointed MSKA & Associates, a member firm of BDO International, as our statutory auditor, effective from quarter two itself, which further reinforces the highest standard of transparency and governance for all our stakeholders.

Yatharth Tyagi executive
#4

We're also happy to report that Crisil has raised our credit rating to Crisil A/Stable, which speaks to how strong our business prospects are. In the quarter, we got Model Town Hospital in New Delhi up and running around mid-July, which added 300 beds to capacity. On top of that, we began operations at a hospital in Faridabad Sector 20, adding 400 beds to capacity. Footfalls are already climbing at both of these new hospitals. Given our advanced infrastructure and clinical team, we expect these two facilities to serve as a major growth driver in the quarters ahead. Carrying forward our expansion strategy, this quarter we also acquired Shantived Hospital in Agra, which has an expanded capacity of 250 beds. That hospital is already operating, so it will contribute meaningfully to revenue and profitability right from day one of integration. We expect that integration to wrap up by H2 of this fiscal itself, and we should be adding revenues and a better of this hospital from quarter four of this financial year. Our dedication to clinical excellence also shows in the various technological adoptions and complex procedures carried out this quarter. We used the newest navigation system and intelligent joint software to carry out Delhi's first-ever robotic intellectual hip revision surgery at the newly opened Model Town Hospital.

Yatharth Tyagi executive
#5

We’ve likewise embraced rapid AI along with sophisticated AI-powered neuroimaging technology to detect stroke quickly and accurately across more facilities, which improves diagnosis and shortens treatment timelines. Those advanced procedures put us in a select group of hospitals in North India that offer this cutting-edge clinical care. We’ve made substantial progress on the medical value travel side as well. During FY 2026, we set up Yatharth representative offices in Baghdad and Tashkent together with Chinor Medical Center, and we are expanding into Cameroon via both institutional and private partnerships. We are also working toward becoming the exclusive healthcare partner for the upcoming Jewar AiARPOBrt, which is expected to boost international patient volumes from those regions, and having Yatharth Hospital’s clinical medical examination room at the Jewar Airport will further raise our visibility among passengers, domestic and international alike, who use the airport. I’d also like to use this opportunity to spotlight a key industry-wide development this quarter: a long-awaited Central Government Health Scheme, CGHS rate revision after more than a decade, effective October 13, 2025. We welcome this step, and the new framework brings rationalized tier-based rates with higher reimbursement for accredited super specialty providers in metros.

Yatharth Tyagi executive
#6

That structural shift is going to meaningfully improve how much revenue we actually realize, and our profitability, at every one of our hospitals. As we look forward, we stay focused on ramping up the new facilities, broadening our super specialty offerings, and pushing operational efficiencies throughout the network. We're confident that these initiatives — together with robust governance practices and a strong management team — will help us deliver sustained value to all our stakeholders. With that, I'd now like to hand the call over to Mr. Pankaj Prabhakar for a detailed financial update.

Pankaj Prabhakar executive
#7

Good afternoon, everyone. I'm happy to report that Yatharth Hospital has posted yet another quarter of record revenue and EBITDA. In quarter FY 2026, revenue came in at INR 2.794 billion, which represents a healthy 28% increase year-over-year and 8% growth quarter-over-quarter. Our newer hospitals were the key growth drivers, posting a significant 110% YOY increase, while our mature hospitals kept up their upward trajectory, reporting a 19% year-over-year increase. Notably, Greater Faridabad, which is just in its first full year of operation, now accounts for 10% of our overall growth revenue, reflecting the strength of our expansion strategy. During the quarter, we added 700 beds with the commencement of our New Delhi and Faridabad hospitals. However, despite that bed addition, our occupancy stood healthy at 66% during the quarter. As far as hospital-wide occupancy is concerned, our Noida Extension facility achieved an occupancy of 89%, Greater Noida at 69%, Noida Extension at 64%, and Jhansi Orchha at 71% during the quarter. Our strategic focus on high-value super specialty care and continued investment in cutting-edge medical infrastructure has resulted in an increase in consolidated ARPOB of INR 32,015 in quarter FY 2026. Notably, mature hospitals, which include Noida, Greater Noida, and Noida Extension, achieved an ARPOB growth of 9% year-over-year, while our newer hospitals registered an ARPOB growth of 19% year-over-year, reflecting our continuing focus on improving the mix.

Pankaj Prabhakar executive
#8

At our Noida Extension hospital, ARPOB reached its highest level ever, INR 40,800, which is a 7% increase year-over-year, supported by roughly 70% of its contribution coming from super specialty services. The Noida hospital posted ARPOB of about INR 31,100, Greater Noida came in at INR 38,300, and Greater Faridabad stood at INR 31,900. Our Model Town New Delhi facility opened during the quarter, with an initial ARPOB of INR 33,600. As we ramp up the Model Town and Faridabad Sector 20 hospitals, we expect them to deliver ARPOB considerably above our group ARPOB. Turning to profitability, EBITDA reached a record INR 645 million, an 18% rise year-over-year. Taking into account the initial operational losses at our newly operationalized Delhi and Faridabad Sector 20 hospitals, adjusted EBITDA was INR 737 million, up 35% year-over-year, and our adjusted EBITDA margin came in at a healthy 26.7%. On that basis, adjusted profit after tax increased 63% year-over-year. Our balance sheet remains robust, with a strong net cash position of INR 3.692 billion, which gives us ample financial headroom to capitalize on suitable growth opportunities. Going forward, we stay optimistic about sustaining our growth trajectory. Our strategic priorities will center on expanding our footprint across North India, optimizing existing clinical infrastructure, enhancing clinical excellence to drive higher ARPOB, and capitalizing on emerging opportunities in the sector.

Pankaj Prabhakar executive
#9

Thanks for listening. At this point, I’d like to pass the call over to the moderator so we can move into the question-and-answer session. Thank you.

Operator operator
#10

Appreciate it, sir. At this point we'll move into the question-and-answer portion. To pose a question, you can hit star and one on your touch-tone phone. Should you want to pull yourself out of the queue, just press star and two. We ask that participants speak through the handset when asking. Ladies and gentlemen, we'll pause briefly while the queue builds up. Our first question comes from Ritika Khandelwal of Perpetuity Ventures. You may proceed.

Ritika Khandelwal analyst
#11

Hi there, and thanks for the chance to ask. I was hoping for a little more clarity regarding the Faridabad and Delhi hospitals — specifically, what size of losses you'd be expecting. Given that Faridabad has just been operationalized and the minority share has been positive — a large minority share — are the Faridabad losses being booked? And what should we expect going forward from those two facilities?

Yatharth Tyagi executive
#12

Looking at Q2, we had roughly 3.3% total dilution in EBITDA as a result of the two new facilities — namely the Faridabad Sector 20 hospital and the New Delhi Model Town hospital. We're fairly confident that within the coming 15 to 17 months, both of these hospitals will reach EBITDA break even. Also, although the Faridabad 20 facility was fully officialized — that is, IPD began on November 1st — before that, for about a month, almost a couple of months, the staffing was already in place. So that's why some of the loss is already showing up, including some doctors, nurses, and admin staff who are all stationed there and getting the hospital ready. Yes, certain of those expenses have been booked in FY 2020, and the hospital will also be fully operationalized, with all expenses fully booked starting from quarter three itself.

Ritika Khandelwal analyst
#13

Could you quantify what sort of losses you're looking at?

Yatharth Tyagi executive
#14

The EBITDA loss for Q2 would be somewhat comparable in Q3 as well, given those two hospitals, since Delhi Hospital will probably be four-five months into operations by then. That EBITDA drag will go down in Q3, but the EBITDA drag for FY 2020 will go up a bit. I think we should see a similar pattern to the Q2 EBITDA loss in Q3 from these two particular hospitals.

Ritika Khandelwal analyst
#15

And then on Delhi — where does the run rate stand at the moment, and what sort of occupancy are you seeing there?

Pankaj Prabhakar executive
#16

Honestly, it's quite soon to give you an occupancy figure right now, since we've only had two to three months of operations. As things stand, I believe 13%-14% of Delhi is already operating. Faridabad has only just begun. As we said earlier, we expect both of these hospitals to reach break even in something like 15 to 16 months. I think we're very much on track for that, right? Yes, more empowerments and then insurances are, I mean, still to come. Once that's done over the next four-five months, I think we would be, and as we said earlier as well, at anywhere between 30 to 35% occupancy, we hit EBITDA break even. That's what we're expecting over the next 15 to 16 months.

Ritika Khandelwal analyst
#17

Alright.

Operator operator
#18

My apologies for cutting in, Ms. Ritika — your audio is cutting out.

Ritika Khandelwal analyst
#19

When does the Agra facility get going?

Yatharth Tyagi executive
#20

The Agra facility is going to be fully on our books starting in quarter four. Around the first week of the new year, we should have that facility up and running. It's a facility that already operates, but from the first day of quarter four it will be consolidated onto our balance sheet.

Ritika Khandelwal analyst
#21

Thanks. And one last thing — could you share the payer mix with us, plus what percentage of professional fees goes to the doctors?

Yatharth Tyagi executive
#22

When it comes to payer mix, the government business accounts for roughly 37%, and everything else splits evenly among private insurance, TPA, and self-pay, meaning the cash payer. Now, regarding your second question: overall, the doctor share — the doctor cost as a percentage of revenue — stands at 21.5%.

Ritika Khandelwal analyst
#23

Alright.

Operator operator
#24

Pardon the interruption, Ms. Ritika, but could we ask you to please get back in the queue, ma'am? Quite a few participants are waiting for their turn.

Ritika Khandelwal analyst
#25

Alright.

Operator operator
#26

Thanks. Ladies and gentlemen, so that management can take questions from everyone waiting in the queue, please limit yourselves to 2 questions per participant. If you have follow-up questions, please get back in the queue. Our next question comes from Nirali Shah of Ashika Stock Service. Please go ahead.

Nirali Shah analyst
#27

Hello, and thanks for taking my question. I wanted to ask about ARPOBs. On your slide, group ARPOB goes from INR 30,395 in one queue to INR 32,015 in two queues. Even though both mature and new hospitals are reporting ARPOB growth, this is the gap we're seeing. Could you walk through the math for us — which hospital or payer segment dragged consolidated ARPOB down QoQ, and what caused that?

Yatharth Tyagi executive
#28

That's because occupancy at Jhansi Hospital has gone up very sharply. Jhansi Hospital has hit 70% occupancy, which is in line with our target, and we're quite pleased about that — it has now become a leading service provider in that area. Since ARPOB at Jhansi Hospital is roughly half the group average, the rise in occupancy there resulted in slower ARPOB growth — not a decrease, but muted growth. That said, with the Delhi and Faridabad 20 hospital ramping up over the coming quarters, and those will carry ARPOB well above the group average, we remain on track for our EBITDA yearly ARPOB growth for the full year, somewhere around 8%-9% compared with last year.

Nirali Shah analyst
#29

Understood. Also, regarding the income tax issue, you mentioned that assets were raised and the FVs were raised. Are there any remaining contingencies, appeal windows, or possible future claims? Any clarity on that?

Yatharth Tyagi executive
#30

Yeah. I think that was a big step forward where the entire matter is concerned. We expect the entire matter to be resolved sometime before — I think before the financial year ends. Probably before the calendar year ends, it will also move considerably toward closure. I think the right timeline ought to be before this calendar year ends.

Nirali Shah analyst
#31

My final question concerns the CapEx plan. During the prior con call, we announced a figure of roughly INR 1,400 crore to INR 1,500 crore across 3 years. I just wanted to ask how much extra debt you intend to take on over the next 12 months in order to fund the brownfield, and what the maximum borrowing cost would be that you could regard as an acceptable level?

Yatharth Tyagi executive
#32

Okay, one clarification I want to make. With the INR 1,500 crore to INR 1,400 crore CapEx planned for 3 years, technically we'll wind up deploying that money across the following 5 years — roughly 4.5 to 5 years. The reason is that, yes, deals tied to that CapEx would be announced within the coming 3 years, but the greenfield expansion we're undertaking comes after those 3 years. Full use of those funds would take about 4.5 to 5 years. Technically, we'll be spending INR 1,500 crore across the next 4.5 years. That's the first correction. The second one: where the next 12 months are concerned, obviously Agra's 250 beds will be with us in Q4, and beyond that we remain committed as well. That means roughly in H1 of the coming financial year, 2027, we should also be looking at adding around 300 to 400 beds via an acquisition or a project in the pipeline that we're currently working on.

Nirali Shah analyst
#33

Understood. May I ask one more question?

Operator operator
#34

Ms. Nirali, could we ask you to get back in the queue, please, ma'am?

Nirali Shah analyst
#35

Of course. I'll get back in line to ask again.

Operator operator
#36

Thanks. Our next question comes from Param Vora, who is on the line from Trinetra Asset Managers. Please go ahead.

Param Vora analyst
#37

Hi there. Thanks for the chance to speak, and well done on a really strong set of figures. Sir, Q2 revenue growth looks robust. Could you unpack how revenue grew this quarter? What drove that growth? Did it come from more patients coming in, or from the mix and the shift of specialties toward high-margin specialty, or perhaps from pricing?

Pankaj Prabhakar executive
#38

Yes. It's a combination. First, definitely, as you mentioned, we still have organic growth in the existing hospitals, whether from a change in mix or some fine-tuning of our current mix. Second is very strong growth, as noted in the commentary, which is a 10% contribution from the new hospital, Faridabad 88, correct? All of these things — we believe that adding a Delhi location and the new one, I mean, Faridabad Sector 20, will contribute much more growth. However, there's still solid room for upward growth at our existing hospitals, whether Greater Noida or Noida Extension.

Param Vora analyst
#39

Alright, thanks.

Operator operator
#40

Thanks. Our following question comes from Akhilesh Rawat, calling in from Riddhanta Vision Private Limited. The line is yours — go ahead.

Analyst analyst
#41

Hello there. Can you hear me clearly?

Operator operator
#42

Yes, go ahead.

Analyst analyst
#43

Yeah, first off, congratulations on the strong numbers. My questions are mostly about international medical value tourism. What are your plans for that in the upcoming financial 2026 and financial 2027?

Pankaj Prabhakar executive
#44

Our team is solid at this point, and our strategies have already been deployed. Not long ago, we opened 2 information centers along with operating centers — 1 located in Tashkent and the other in Iraq. Several additional ones will be arriving in the African market. I believe we've pinpointed the pockets, and during this financial year, the strategy is extremely clear in my view: we'll launch roughly 5 to 6 information centers, and we're building out — we're actively working on channel partners, whether in that specific country or locally. Our belief is that in this financial year, and likely the H1 of the next financial year, international business will deliver a very strong percentage contribution, since airport results is also set to begin by probably the end of this financial year.

Analyst analyst
#45

All right. So what sort of ARPOB increase are you observing from this? Can you put a number on that?

Pankaj Prabhakar executive
#46

Look, I'd say domestic is always somewhere in the neighborhood of 45% to 55% or more of the total. From that, you can work out the rest.

Analyst analyst
#47

My final question concerns the Agra hospital. When will that hospital's results start showing up in our books?

Yatharth Tyagi executive
#48

As I said before, starting in quarter four of this financial year.

Analyst analyst
#49

Alright, so what sort of ARPOB should we be expecting from that hospital ARPOB?

Yatharth Tyagi executive
#50

I'd say starting out at INR 30,000 or above, roughly in that neighborhood, and then gradually, as we bring more super specialties on board, this genuinely could reach around the group average ARPOB, and perhaps even a little beyond that down the road if we can manage it.

Analyst analyst
#51

Alright. Alright. Alright. That's all from me. Thanks. Thanks, and best of luck for the quarters ahead.

Operator operator
#52

Thanks. Our next question comes from Akshath Mehta at Seven Rivers Holding. Go ahead.

Akshat Mehta analyst
#53

Hi there. Thanks for taking my question, and congratulations on the strong results. I've got a few things to ask about. First, at the Delhi hospital we recently opened, we had previously guided toward an ARPOB figure in the 39,000 to 40,000 range, yet this quarter you posted an ARPOB of roughly 34,000. Could you walk us through the reason for that? Where does that gap come from?

Pankaj Prabhakar executive
#54

Look, on Delhi, I’d say it’s too early to make a judgment. There’s still no insurance, not even cashless patients. At the start, we set a very early rate in the market. Over the next 2 to 3 months, once our tariffs and everything are frozen in line with the competition, the insurance negotiations have taken place, and more and more international patients are flowing into that particular hospital, you’ll see ARPOB much higher than what you’re seeing right now. What we said earlier is absolutely realistic. Whenever a hospital launches, usually the first few months are needed for ARPOB to build. In fact, we’re quite happy that in the very first month, it began at INR 33,000 ARPOB. That gives us confidence that within 12 months or even sooner, this ARPOB can cross INR 40,000. That’s the trend we’ve also seen at other hospitals when we started them.

Akshat Mehta analyst
#55

Alright, sir. For the next question, I'd like to get a handle on the losses we've seen from the new hospitals — which will keep going in Q3 and probably Q4 as well, since Shantived will be adding too — so what kind of margins should we expect on a full-year basis?

Pankaj Prabhakar executive
#56

Given the additional hospitals coming on board, I believe we could even exceed 30% revenue growth. If you could also give guidance on that. Agra won't be a bigger drag, because by Q4 it is already a positive hospital and even profitable. There will be no drag from Agra. That's one. Second, regarding margins, I think what we closed H1 at, somewhere around that would be a realistic figure for the full year as well, maybe 0.5% up or down. I think the margins we already have won't be dragged down further. We are quite confident that even for the quarter two margins shown here, it will only be upside from here for the entire financial year. Agra will be positive from day one. Lastly, on your question about 30% revenue growth, yes, I think that's easily visible. I think we are actually being a bit conservative when we say 30% revenue growth. We feel that this number should be easily overachieved.

Akshat Mehta analyst
#57

Yes, sir. My next question is also about overall CapEx. Sir, this year, and what about next year—what kind of CapEx are we seeing that you spend?

Pankaj Prabhakar executive
#58

I believe we've already provided the guidance covering the next four to four and a half years, which is INR 1,500 crore of CapEx, and I think we'll simply stay with that figure. Our cash position is solid. We carry no debt, and we're producing strong internal accuracy. So whatever CapEx is needed, the company will be more than capable of funding it itself.

Akshat Mehta analyst
#59

Thank you. Sir, I have one more question.

Operator operator
#60

My apologies, Mr. Akshath, but could we ask you to please get back in the queue, sir?

Akshat Mehta analyst
#61

Sure.

Operator operator
#62

Thanks. The next question comes from Surya Narayan Nayak at Sunidi Security & Finance Limited. Go ahead.

Surya Narayan Nayak analyst
#63

Yes. Can I jump in here, sir?

Operator operator
#64

Yes, please, go right ahead.

Surya Narayan Nayak analyst
#65

Thanks for the chance to speak, and congratulations on the strong results. Just one point on the Agra hospital: when we acquired it, my understanding is that it was running at roughly 40% occupancy, and we've planned to expand it to 250. Over what timeframe will those hospitals be ramped up? I understand it will function as a feeder hospital. When will we be in a position to bring in all types of super specialties there, and when can we expect to achieve an ARPOB of at least 35,000+? That's my first question.

Yatharth Tyagi executive
#66

Agra isn’t something we view merely as a feeder hospital. Agra is a large standalone 250-bed super specialty hospital. As a market, Agra is very fertile. In that region, we are the first corporate hospital, and it has a huge population not only of Agra but also of nearby places such as Hathras, Saifai, Etawah, and Shikohabad. All these patients drain to Agra, and a facility at this level combined is not there across that whole region. Agra will be a full standalone super specialty hospital where all the super specialties will be provided by us. It will be on our books starting January itself of the next calendar year. We will begin with 150 beds, but to reach that 250-bed expansion, no more CapEx is needed from us. Only beds need to be added. The whole infra there is almost ready for 250 beds. As and when required, according to occupancy, we will see, and we will simply keep opening floors and putting in beds there. As far as the ARPOB full measure is concerned, let me remind you that since it is already a running hospital, it will not take us long to develop super specialties, because a cath lab is already there, cardiac surgery is happening there, and angioplasties are happening there.

Yatharth Tyagi executive
#67

That hospital already has a lot of super specialties in place. When it comes to the Agra hospitals, we expect a very strong and very fast ramp-up in both ARPOB super-specialties and occupancy.

Surya Narayan Nayak analyst
#68

All right, going back to a point Alisher raised earlier — when you factor in the two quarters, the heat, and the cost absorption tied to the new hospital, what's the EBITDA margin guidance for FY 2026? And will those costs be fully absorbed by then, so that no further loss shows up in FY 2027?

Yatharth Tyagi executive
#69

No. As we mentioned before, regarding the EBITDA margin for this quarter, there is only upside ahead, and that will materialize in the upcoming quarter as well as across the entire financial year. It will be fully absorbed, because yes, we will also be adding capacity next year. This year, technically speaking, we have added capacity including Agra, and we will continue adding. Over the full financial year, we would be adding 1,000 beds. That represents three new hospitals that have come up. Even with those three new hospitals during our financial year, we are able to keep margins above 23% of EBITDA. Anything in the future will be upside from here only.

Surya Narayan Nayak analyst
#70

Sir, on the —

Operator operator
#71

My apologies for cutting in, Mr. Surya. Could we ask you to get back in the queue, sir?

Surya Narayan Nayak analyst
#72

Sir, I have just one more question to ask.

Operator operator
#73

Sir.

Surya Narayan Nayak analyst
#74

Alright, may I go ahead, sir?

Operator operator
#75

Yes, sir, please continue.

Surya Narayan Nayak analyst
#76

Alright, thanks. Now, regarding that long-term goal of INR 1,500 crore in CapEx across 4.5 years — is it fair for us to assume that the consolidation of these extra 1,000 beds will come first, and only after that might you consider inorganic routes, given that brownfield plans are also in the works going forward? Can we take it that you'd expect some consolidation at the existing new facilities first, and then look at expansion — say, inorganic expansion — and would that inorganic expansion stay limited to the NCR region or the periphery of NCR? That's really what I'm trying to understand.

Yatharth Tyagi executive
#77

For the rest of this financial year, at least, no extra capacity is going to be brought into use. We may launch a greenfield project before long, but bringing that capacity online will take time. As for these hospitals, since our target is 15 months, they are reaching break-even. It isn't as though we must wait a long time, first to consolidate and only then to add capacity. I think we are in a very good position right now as well — not this financial year, but perhaps the next financial year — to add further acquisitions, further hospitals, in H1 itself, and that is the plan. On your second question, regarding location and geographies, we believe the markets where we operate — that is the NCR market, the entire North India market of large cities in UP, Haryana, Punjab, Rajasthan. I think we want to be in metro cities. We want to be in large cities. Technically, they will not be only peripheral hospitals. Every one of our hospitals, so far, if you look at the last few quarters, we have added in the core Delhi and Faridabad market, which are large cities. That is what we wish to keep doing going forward.

Yatharth Tyagi executive
#78

Agra is another major city in UP. These are the large metro areas where we aim to have a presence in the years ahead as well.

Surya Narayan Nayak analyst
#79

What ARPOB cut have you set here?

Yatharth Tyagi executive
#80

I’m sorry — could you say that again?

Surya Narayan Nayak analyst
#81

When you're looking at new acquisitions, what ARPOB threshold do you have in mind? In other words, is there a certain level below which you wouldn't want to consider a property, depending on location? Is that figure 35,000?

Yatharth Tyagi executive
#82

Yes. I'd say that figure or higher — that ought to be the floor. That is the standard.

Surya Narayan Nayak analyst
#83

Alright. Thanks a lot.

Operator operator
#84

Thanks. Before we take the next question, just a reminder for everyone on the call: please limit yourselves to 2 questions only. If you have a follow-up, please rejoin the queue. Our next question comes from Dhaval Sangoi of Canara HSBC Life Insurance. Please go ahead.

Dhaval Sangoi executive
#85

Yeah. Hi. Thanks for the chance to ask. Yatharth, I just wanted to get your take on the CGHS rate revision that took effect from October. Have we seen any benefit coming through from that, and does it affect us in any positive way?

Yatharth Tyagi executive
#86

Right. So the CGHS rate came into effect just recently, back in October. When we look at the upside, CGHS revenue should land at roughly 1.5% in FY 2026, and the EBITDA benefit comes to about 1% this financial year — that could climb to 2.5% on the revenue side next year, with around 1.75% on the EBITDA side.

Dhaval Sangoi executive
#87

All right, so if we take the 37% of government revenues that you have as the base, we'd see an incremental benefit on top of that amounting to 1.5%?

Yatharth Tyagi executive
#88

Yes. Does it help on price? It does. There will be a benefit for the company. The rate revision is going to contribute to higher ARPOB as well, and it will be a benefit to the company.

Dhaval Sangoi executive
#89

All right. That's all for the moment. Thanks.

Operator operator
#90

Thanks. Our next question comes from Naveen Baid at Nuvama Asset Management. Go ahead, please.

Naveen Baid analyst
#91

Thanks for the chance to speak, and those sales figures are excellent. I mean, looking at how things have moved across the last six or seven quarters, your ROS has been declining, and at the same time your occupancy ratios have climbed. In a sense, your throughput has risen quite markedly. How do you account for ROS falling across those six quarters — from roughly 4.8, 4.9 down to the 4.06 we're reporting this quarter?

Pankaj Prabhakar executive
#92

Bringing in those new technology sets, such as robotics, has cut your LOS considerably, correct? Top-tier specialty, cutting-edge infrastructure. That is something that previously—let me give you an illustration—for any laparoscopic procedure where a patient would formerly remain for 3, 3.5 days or around 4 days, now that patient can be discharged in as little as 2 days, right? The addition of new technology has had a major part in lowering the LOS, along with very, very, very novel treatment modalities. This also has a part to play.

Naveen Baid analyst
#93

So if that holds true, shouldn't your ARPOB have risen by a lot more than it actually did? Even setting aside the government portion, which is roughly 37%, your ARPOB is up only around 5%–6% across the past six quarters, and that's in spite of a meaningful shift in case mix. How do you account for that? Do you see meaningful room for your ARPOB to climb over the coming four to six quarters?

Pankaj Prabhakar executive
#94

You should look at the figures from that established hospital, especially at Noida Extension, where we have all those modality sets and new technologies. There, ARPOB has gone up considerably, correct? It isn't the case that you simply observe INR 1 of increase here and INR 1 of increase there, but I think that's how it ought to play out. Our belief is that as capacity continues to ramp up in those super specialties, we believe — I believe — that ARPOB will rise as well. And over the last two, three years, on a yearly basis, we have demonstrated 8%-10% ARPOB growth. I think for the coming three years too, we do expect 8%-10% ARPOB growth yearly. Particularly now, with the Delhi market and the larger Faridabad hospital having oncology, transplant, and a growing international share, that ARPOB will be a huge lever for us going forward as well, if we continue to be, as I mentioned, big in metro cities. Naturally, a market such as Jhansi Orchha would have been a drag on ARPOB. If we are expanding our facilities here at Noida Extension in Delhi, ARPOB should rise considerably at a quicker pace as capacity comes up in these new hospitals.

Naveen Baid analyst
#95

Sure, one final question, picking up where the last participant left off. If the government portion of revenue sits at roughly 37%-odd, then when I factor in the full-year effect for next year, wouldn't 2% be overly cautious — or is that simply what your case mix is telling us, that blended equity will come in at 2%?

Pankaj Prabhakar executive
#96

My guess would be 2.5%.

Naveen Baid analyst
#97

Yes, go right ahead.

Pankaj Prabhakar executive
#98

Yes, please continue.

Naveen Baid analyst
#99

Also, sir, could you break down the government revenues between the portion that comes through CGHS and the portion that doesn't go through CGHS?

Yatharth Tyagi executive
#100

Yes. 2.5% is the floor we've conservatively guided to. Any upside beyond that, we'll capture. I think a 2.5 figure is realistic, because with 37% revenue, not all of that revenue will come under the new rate revision scheme. There's a portion — for instance, we do some Aayushman at Jhansi Orchha Hospital, and Aayushman doesn't qualify for or benefit from these schemes. Overall, when we've done the math, at a bare minimum we should see a 2.5% gain next year on total revenue, not CGHS. Total revenues, yes — the overall revenue upside is 2.5%. The entire company stands to gain substantially from this rate revision. 2.5% of total revenue, as you can imagine, is a large amount that will benefit us next year and in the years ahead as well.

Naveen Baid analyst
#101

Understood, understood. That's everything, sir. Many thanks.

Operator operator
#102

Thanks. Everyone, so management can get to questions from every participant on this call, please limit yourself to just one question. Our next question comes from Sumit Gupta at Centrum Broking. Go ahead.

Sumit Gupta analyst
#103

Hey there, thanks for taking my question. So I have two questions. First, is there room for additional margin improvement at the mature facilities?

Yatharth Tyagi executive
#104

Yes, there is, since mature capacities still have room available to use. When we mature hospitals, calling them mature doesn't imply they're maxed out on occupancy. Take Noida Extension and Greater Noida, for instance — both can get to optimized utilization of 75% occupancy. That leaves 10% of headroom for occupancy to rise, and that flows straight through to the EBITDA. Yes, our mature facilities also have room for EBITDA expansion. Okay. Because across the last one and a half, two years, I think it sits in the 26%-27% range. And most of the drag, obviously, comes from the new hospital. So this 27% can get to roughly 28.5%-29% in the years ahead.

Sumit Gupta analyst
#105

So, Noida Extension would be operating at a margin of roughly 32%-33%. If I've got that right — really, what I want to ask about is both Noida Extension and Greater Noida.

Yatharth Tyagi executive
#106

Yeah. I mean, it's not that high. Like I mentioned, we've also made quite a few recent additions when it comes to spending on doctors and star doctors over the last 1 year. Looking ahead, a lot of that spending is happening now that took place across a span of 1 year. Going forward, we expect to see an upside from that spending, which should help drive the figures you're referring to.

Sumit Gupta analyst
#107

Got it. Okay, so that extra 300 to 400 beds of M&A you intend to complete across the coming 12 to 15 months — has that already been referenced? And does it come on top of the CapEx plan laid out in the presentation?

Yatharth Tyagi executive
#108

That figure does include the INR 1,500 of CapEx.

Sumit Gupta analyst
#109

Alright. Alright. Fine. Thanks a lot.

Operator operator
#110

Thanks. The next question comes from Gartha Jain at Anantnath Skycon Private Limited. Go ahead, please.

Analyst analyst
#111

Hello, sir, and thanks very much for the chance. I have just 2 questions. The first is this: how much does it cost to set up a bed at a mature hospital or at a developing one, and how many days pass before that bed breaks even?

Yatharth Tyagi executive
#112

If you were building greenfield in NCR today, the CapEx would run you about INR 1 crore per bed, at minimum for our brand. That's the level we'd be investing. It takes roughly, I'd say, 15 to 18 months, and as a brand we personally aim for break even within that window after the hospital becomes operational. In a brownfield scenario, that CapEx per bed could come in at around INR 7.5 million per bed, since much of the medical equipment is already there in one tower. Brownfield expansion costs somewhat less than the greenfield expansion figure of INR 10 million CapEx per bed.

Analyst analyst
#113

What's the timeframe for reaching break-even on brownfield?

Yatharth Tyagi executive
#114

Typically, for the new brownfield expansion projects, our EBITDA break-even point is roughly 15 months.

Analyst analyst
#115

Okay, understood. And what would the overall count be?

Operator operator
#116

My apologies for cutting in, Ms. Jain. Perhaps I could ask you to reach out.

Gartha Jain analyst
#117

Of course. Of course.

Operator operator
#118

Thanks.

Gartha Jain analyst
#119

I really appreciate it.

Operator operator
#120

The following question comes from Tripti Shukla at KDA Securities Private Limited. You have the floor.

Analyst analyst
#121

Hello, sir, and thank you for the opportunity. My question concerns the working capital rate. Receivables have risen meaningfully for this quarter, while the cash balance has fallen because of CapEx and working capital needs. Could you elaborate on which specific receivable bucket is stretching the cycle, and by when debtor payments should normalize? Also, when do you expect operating cash flow to return to the historical level of 70%-80%?

Pankaj Prabhakar executive
#122

As you can see, our debtor days have come down. What we projected earlier in our earnings call, we've delivered on that as well. This time around, we've cut debtor days by 8 to 10 days. We're quite confident that the same trend will continue, and we will achieve that same reduction of 8 to 10 days as of March 2026. Okay. Next question. Next question.

Analyst analyst
#123

One more question. Yes, sir.

Pankaj Prabhakar executive
#124

Pardon me?

Analyst analyst
#125

Yes, sir.

Pankaj Prabhakar executive
#126

On the cash flow question?

Analyst analyst
#127

Yes, sir.

Pankaj Prabhakar executive
#128

Yes. On cash flows, our OCF2 beta sits at 58% right now. We've revised the policy. Previously, salaries went out on the next imminent day of a month. At present, we align salary payments with the competition, with the peers. We now disburse on that same last day of a month. If we neutralize that effect, OCF2 beta comes in at roughly 78%. That's better than what we reported earlier.

Analyst analyst
#129

Alright, sir, thank you. That’s everything from my end.

Operator operator
#130

Thanks. Our next question comes from Vidisha at CRK. Go ahead, please.

Analyst analyst
#131

Hi there. I'd like to follow up on the EBITDA margin. You mentioned that from here on it will only move upward. With the additional capacity that's arriving down the road, I'm curious how you expect the EBITDA margin to improve even more. Wouldn't that bring some margin dilution?

Yatharth Tyagi executive
#132

No. You won't see any margin dilution, because as we said earlier, we've still added 700 beds in only one quarter and still hold this base margin. Looking ahead, there's no plan to add 700 beds in a single quarter, at least for the next four or five quarters. The margin only has upside. In fact, if you look at it, we clearly mentioned that excluding the capacity expansion we've done, our EBITDA margins would have been close to 26.5%. That's why we feel confident that when these new facilities start ramping up on occupancy, a big margin expansion should happen in the coming years.

Analyst analyst
#133

Okay, could you walk me through it?

Operator operator
#134

Pardon the interruption, Ms. Shah. Could we ask you to get back in the queue, please? A lot of participants are waiting for their chance.

Vidisha Shah analyst
#135

This is my second question.

Operator operator
#136

Ma'am, we’re limiting everyone to just one question, so please get back in the queue. Thank you. Just a reminder for all participants: kindly keep it to a single question per person. Our next question comes from Anand B at Ksema Wealth Private Limited. Please go ahead.

Anand Bhaskaran analyst
#137

Good afternoon, sir. Are you able to hear me?

Operator operator
#138

Yes, go ahead.

Anand Bhaskaran analyst
#139

Yeah, I just want to ask about the CapEx — sorry, not CapEx — the census beds for each of the hospitals this quarter.

Yatharth Tyagi executive
#140

As of today, we have a census of roughly 750 for all the capacity we're operating.

Anand Bhaskaran analyst
#141

Is it also splitting out between the older and newer capacities?

Yatharth Tyagi executive
#142

Are you asking for the breakdown by unit?

Anand Bhaskaran analyst
#143

Sure. Sure. Let's take it hospital by hospital.

Yatharth Tyagi executive
#144

At the Greater Noida facility, we have 330 beds, census beds. In Noida, we have 215 beds. At Noida Extension, we have 390 beds. Jhansi Orchha, we have around 250 beds. Greater Faridabad, Sector 88, we have 150 beds. The rest of the new facility we just added in this quarter and we just started in New Delhi as well. We have been to a ramp-up stage of nearly around 150 each. That comes to around 1,750.

Anand Bhaskaran analyst
#145

Alright. Thanks a lot.

Operator operator
#146

Thanks. Our next question comes from Santosh Singh at Asha Investments Fund. You have the floor.

Analyst analyst
#147

Hello, sir. Good afternoon, sir.

Pankaj Prabhakar executive
#148

Yes. Good afternoon.

Analyst analyst
#149

Good afternoon, everyone, and thanks for your patience. I’ve got one question, sir. Could you walk us through why a refinancing loan of INR 516 crore was taken in this quarter? Also, which subsidiary received that loan? What kind of business does that subsidiary operate? And what is the loan meant for—working capital, expansion, or some particular project?

Yatharth Tyagi executive
#150

So essentially, this is a subsidiary that we've recently brought in. That new hospital — the one we added over in Sector 20, Faridabad — is among the subsidiaries for which the capital outlay has been laid out per the object clause. The money was raised through the QIP. There's no loan involved in any of it, though it does serve as a sort of object for the depletion and for deployment toward the CapEx as well as the hospital's expansion.

Analyst analyst
#151

All right, sir, thank you. I understand.

Yatharth Tyagi executive
#152

Thanks. Our debt levels right now sit at nearly zero. In fact, the company carries no debt at all. As things stand today, neither the holding company nor any of its subsidiaries has any current debt outstanding.

Operator operator
#153

Thanks. Our next question comes from Abhay Sahukar at Convergence Capital. Please go ahead.

Abhay Sahukar analyst
#154

Yeah, thanks for the chance to ask, and congrats on a solid set of numbers. I just wanted to find out what initiatives you've taken to deepen the clinical program? Are there particular specialty lines — cardiac, neuro, or oncology, say, or anything else — that are ramping up faster at any of the units?

Pankaj Prabhakar executive
#155

We’ve been looking at things unit by unit. What we’re seeing is what’s out there in the market. We noticed the gap we have in super specialty and quaternary care, correct? About 18 months ago, we launched at a flexible hospital in Noida Extension with a full range of cancer treatment and every transplant program. In the same way, in Greater Noida, we began our kidney and liver transplant program. Delhi is certainly going to become a full-fledged quaternary care hospital, transplant included. Faridabad likewise. Which clinical treatment modalities get added depends on the area where we operate and what competitive advantages we gain by bringing in those specialties or facilities. Likewise in Agra too, we foresee that we will definitely have complete tertiary care facilities in that region, possibly including long-term cancer, right? That’s how we assess it — which gray areas require investment, what the ROI would be, all those things, metrics, bobs.

Abhay Sahukar analyst
#156

That’s great. Thanks very much, sir. I just wanted to ask a quick follow-up on that point.

Operator operator
#157

Apologies for cutting in, Mr. Sahurkar. Could I ask you to get back in the queue for the follow-up questions, sir?

Abhay Sahukar analyst
#158

Absolutely, sir. Thank you very much.

Operator operator
#159

Our next question comes from Prerana Amanna at Equity Research Programs. Please proceed.

Prerana Amanna analyst
#160

Yes, I’ve had everything I asked about covered. Thanks.

Operator operator
#161

Thanks. Our next question comes from Anand Kulkarni at Front Wave Research. Go ahead.

Anand Kulkarni analyst
#162

Hello, and thanks for taking my question. I just have one thing I'd like to ask. Could you update us on where things stand with the brownfield expansion at the Greater Noida and Noida Extension hospitals? Once we get past FY 2028 and hit our goal of 3,000 beds, when should we expect that? And how are we viewing our strategy for expanding beds? Thank you.

Yatharth Tyagi executive
#163

Yes. I believe the capacity at both of these hospitals ought to become available for our use roughly 15 months from today. So 15 should be Greater Noida, and Noida Extension should be maybe 17 to 18 months from today. Since we will add the 3,000-bed capacity by 2028, I think we should cross it much more even earlier because there's something planned next year in terms of acquisitions concerned. In fact, we have revised our bed capacity target. Rather than now talking about 3,000 beds in 2028, the bed capacity would be much more for next three years from today. With the Agra addition, we would be around 2,550 beds. We feel that probably in the next 3 to 4 years, there is still scope in the company to even close to double this capacity in the next three to four years, including all these brownfield expansions that are already in place, the upcoming acquisitions, and one more greenfield that the company is planning very soon within the NCR region. I think we are looking at a much bigger bed capacity after 4 years from today. Great. That really answers the questions. Thank you so much and all the very best.

Operator operator
#164

Thanks. Our next question comes from Abhijit at PISH. Go ahead, please.

Analyst analyst
#165

Appreciate the chance to ask. I have just one question. A GST rate cut applies to consumables, agents, and chemicals. So is it safe to assume we can keep that benefit?

Pankaj Prabhakar executive
#166

One GST change is certainly going to be beneficial for us. It should contribute roughly 0.3%-0.5% of total revenue. The EBITDA impact of that will be just 0.3%-0.5%.

Analyst analyst
#167

Right. All right, thanks.

Pankaj Prabhakar executive
#168

Much appreciated.

Operator operator
#169

Thanks. The next question comes from Nirali Shah at Ashika Stock Service. Go ahead.

Nirali Shah analyst
#170

Yes. I just wanted to follow up regarding the cost of borrowing. So, what's the maximum cost of borrowing that you would consider acceptable?

Yatharth Tyagi executive
#171

On that front, we don't carry that kind of debt on the books. But whenever we do take on debt, should the need arise, it typically ends up at roughly a 7.5%-8% coupon rate from the PSU banks.

Nirali Shah analyst
#172

Alright. For FY 2028, we're steering toward 40,000 ARPOBs, and we're holding steady on that.

Yatharth Tyagi executive
#173

We expect growth of 8% to 10% each year starting now. I believe we're fairly confident we can get there.

Nirali Shah analyst
#174

All right, that's useful. Thanks.

Operator operator
#175

Thanks. Our next follow-up comes from Akshat Mehta, who is calling in from Seven Rivers Holding. Please go ahead.

Akshat Mehta analyst
#176

Hi, sir. Just a quick accounting question, sir. During this quarter, or across this half year, we have noticed a modest decline in cash flow from operations. Other financial liabilities have risen somewhat. Could you help us get a handle on what that is?

Yatharth Tyagi executive
#177

As I said earlier, there’s been a shift in policy. The company has decided to align salary payments with what peers do. At this point, we’ve begun paying salaries on the final day of each month. That’s the reason for the movement in other financial liability.

Pankaj Prabhakar executive
#178

Yeah. We get paid on day one of each month.

Yatharth Tyagi executive
#179

Yes.

Akshat Mehta analyst
#180

Alright. Alright, sir.

Operator operator
#181

Thank you. Ladies and gentlemen, we'll treat this as today's final question. At this point, I'd like to turn the conference back to management for closing remarks.

Yatharth Tyagi executive
#182

I appreciate all of you joining us for Yatharth Hospital & Trauma Care Services Limited's earnings call covering FY 2026. We're grateful to have you here.

Operator operator
#183

Thank you, sir. This conference is now finished on behalf of Elara Capital. We appreciate everyone for participating, and you're welcome to hang up your lines at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Yatharth Hospital & Trauma Care Services Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Yatharth Hospital & Trauma Care Services Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.